000403.SZ
000403.SZ
CNE000000F14
PLBIO
Loading chart...

Company Profile

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cytomegalovirus immunoglobulin and intravenous respiratory syncytial virus immunoglobulin. It is also involved in blood acquisition; plasma collection; consulting; trading; investment activities; and technology promotion and application services. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.

Related stocks

2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
688739.SS
688739.SS • China
LIAONING CHENGDA BIOTECHNOLOGY
21.2 CNY
1.32B USD 1Y -21.9%
002030.SZ
002030.SZ • China
DAJY
6.03 CNY
1.27B USD 1Y -6.1%
9887.HK
9887.HK • China
LEADS BIOLABS-B
45.56 HKD
1.15B USD 1Y -37.5%
688177.SS
688177.SS • China
BIO THERA SOLUTIONS LTD
19.3 CNY
1.2B USD 1Y -31.6%
300204.SZ
300204.SZ • China
STAIDSON BIO
20.66 CNY
1.67B USD 1Y -38.7%
300294.SZ
300294.SZ • China
BOYA BIOLOGY
14.88 CNY
1.12B USD 1Y -40.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.9% p.a.
Max Drawdown (5Y)
-73.6%
Sharpe Ratio (5Y)
-0.55
Beta Factor
0.43
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -82.4% in the extended horizon.
ende